{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:19:15Z","timestamp":1790291955538,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:00:00Z","timestamp":1637971200000},"content-version":"am","delay-in-days":361,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jbspin.2020.09.014","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T10:11:21Z","timestamp":1600855881000},"page":"647-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis"],"prefix":"10.1016","volume":"87","author":[{"given":"Esther","family":"Ebstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Forien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Norkuviene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Richette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebl","family":"Mouterde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Daien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang-Korng","family":"Ea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Liot\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mykolas","family":"Petraitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Ora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Dieud\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Ottaviani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2020.09.014_bib0135","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","article-title":"Gout","volume":"375","author":"Richette","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0140","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0145","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0150","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/ken457","article-title":"Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study","volume":"48","author":"Schumacher","year":"2009","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0155","first-page":"746","article-title":"Ultrasound sensitivity to changes in gout: a longitudinal study after two years of treatment","volume":"35","author":"Peiteado","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0160","first-page":"1888","article-title":"Ultrasonographic measurement of tophi as an outcome measure for chronic gout","volume":"34","author":"Perez-Ruiz","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0165","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jbspin.2014.03.011","article-title":"Ultrasound in gout: a useful tool for following urate-lowering therapy","volume":"82","author":"Ottaviani","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0170","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/rheumatology\/key303","article-title":"Ultrasound evaluation in follow-up of urate-lowering therapy in gout: the USEFUL study","volume":"58","author":"Ebstein","year":"2019","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0175","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0180","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. report of a task force of the eular standing committee for international clinical studies including therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0185","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/art.40381","article-title":"Brief report: validation of a definition of flare in patients with established gout","volume":"70","author":"Gaffo","year":"2018","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0190","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/art.33483","article-title":"Developing a provisional definition of flare in patients with established gout","volume":"64","author":"Gaffo","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0195","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","article-title":"EULAR evidence based recommendations for gout Part I: diagnosis. report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0200","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1002\/art.39254","article-title":"2015 Gout classification Criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"67","author":"Neogi","year":"2015","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0205","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-018-1714-9","article-title":"Monosodium urate burden assessed with dual-energy computed tomography predicts the risk of flares in gout: a 12-month observational study: MSU burden and risk of gout flare","volume":"20","author":"Pascart","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0215","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.semarthrit.2012.03.010","article-title":"Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy","volume":"42","author":"Schlesinger","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0220","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0225","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0230","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0235","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0240","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semarthrit.2018.02.009","article-title":"Serum urate as surrogate endpoint for flares in people with gout: a systematic review and meta-regression analysis","volume":"48","author":"Stamp","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0245","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13075-015-0701-7","article-title":"A prospective evaluation of ultrasound as a diagnostic tool in acute microcrystalline arthritis","volume":"17","author":"Zufferey","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0250","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/art.39959","article-title":"Performance of ultrasound in the diagnosis of gout in a multicenter study: comparison with monosodium urate monohydrate crystal analysis as the gold standard","volume":"69","author":"Ogdie","year":"2017","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0255","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/ard.2007.070755","article-title":"Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations","volume":"66","author":"Roddy","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2020.09.014_bib0260","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41927-019-0075-6","article-title":"The challenges of gout flare reporting: mapping flares during a randomized controlled trial","volume":"3","author":"Teoh","year":"2019","journal-title":"BMC Rheumatol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20301780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X20301780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:27:41Z","timestamp":1761150461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X20301780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1297319X20301780"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.09.014","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"UltraSound evaluation in follow-up of urate-lowering therapy in gout phase 2 (USEFUL-2): Duration of flare prophylaxis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2020.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}